Previous close | 3.8500 |
Open | 3.8000 |
Bid | 3.7500 |
Ask | 5.6500 |
Strike | 165.00 |
Expiry date | 2026-01-16 |
Day's range | 3.7000 - 3.8500 |
Contract range | N/A |
Volume | |
Open interest | 22 |
Merck & Co., Inc. ( NYSE:MRK ) just released its quarterly report and things are looking bullish. The company beat...
On Thursday, U.S. drug maker Merck & Co Inc (NYSE:MRK) reported first-quarter sales of $15.8 billion, up 9% year-over-year, beating the consensus estimate of $15.2 billion. Excluding the impact of foreign exchange, sales increased 24%. Merck reported adjusted EPS of $2.07, up 48%Y/Y, beating the consensus of $1.88. Merck’s pharmaceutical unit booked $14.01 billion in revenue during the first quarter, up 10% Y/Y. Related: Merck’s $11B Bet Pays As FDA Approves Sotatercept For Rare Lung Disease. Me
Merck (MRK) beats first-quarter estimates for earnings and sales. The company raises its EPS range for 2024. Stock rises in pre-market.